Stay up to date on recent advances in the multidisciplinary approach to cancer.
Zanubrutinib Shows Enhanced Efficacy vs Approved BTKis in R/R CLL
A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.
Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.
3 Things You Should Know About Unresectable NSCLC
In first-line, EGFR-mutated NSCLC, targeted therapies such as osimertinib or amivantamab plus lazertinib are recommended.
Fostering the Future of Psychosocial Care With World Psycho-Oncology Day
Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.
Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC
A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.
Multicancer Early Detection Test Showed Clinical Benefit, Minimal Distress
Patients with a cancer signal detected via multicancer early detection test demonstrated similar results to those who did not in the PATHFINDER cohort study.
